Literature DB >> 14985456

Predicting continuous values of prognostic markers in breast cancer from microarray gene expression profiles.

Sofia K Gruvberger-Saal1, Patrik Edén, Markus Ringnér, Bo Baldetorp, Gunilla Chebil, Ake Borg, Mårten Fernö, Carsten Peterson, Paul S Meltzer.   

Abstract

The prognostic and treatment-predictive markers currently in use for breast cancer are commonly based on the protein levels of individual genes (e.g., steroid receptors) or aspects of the tumor phenotype, such as histological grade and percentage of cells in the DNA synthesis phase of the cell cycle. Microarrays have previously been used to classify binary classes in breast cancer such as estrogen receptor (ER)-alpha status. To test whether the properties and specific values of conventional prognostic markers are encoded within tumor gene expression profiles, we have analyzed 48 well-characterized primary tumors from lymph node-negative breast cancer patients using 6728-element cDNA microarrays. In the present study, we used artificial neural networks trained with tumor gene expression data to predict the ER protein values on a continuous scale. Furthermore, we determined a gene expression profile-directed threshold for ER protein level to redefine the cutoff between ER-positive and ER-negative classes that may be more biologically relevant. With a similar approach, we studied the prediction of other prognostic parameters such as percentage cells in the S phase of the cell cycle (SPF), histological grade, DNA ploidy status, and progesterone receptor status. Interestingly, there was a consistent reciprocal relationship in expression levels of the genes important for both ER and SPF prediction. This and similar studies may be used to increase our understanding of the biology underlying these markers as well as to improve the currently available prognostic markers for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985456

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  8 in total

1.  Transcriptomic signature of cell lines isolated from canine mammary adenocarcinoma metastases to lungs.

Authors:  M Król; J Polańska; K M Pawłowski; P Turowski; J Skierski; A Majewska; M Ugorski; R E Morty; T Motyl
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

2.  FRACTALS WITH POINT IMPACT IN FUNCTIONAL LINEAR REGRESSION.

Authors:  Ian W McKeague; Bodhisattva Sen
Journal:  Ann Stat       Date:  2010       Impact factor: 4.028

3.  Network-based de-noising improves prediction from microarray data.

Authors:  Tsuyoshi Kato; Yukio Murata; Koh Miura; Kiyoshi Asai; Paul B Horton; Tsuda Koji; Wataru Fujibuchi
Journal:  BMC Bioinformatics       Date:  2006-03-20       Impact factor: 3.169

4.  Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer.

Authors:  Jiaxu Wang; Rebecca O Barnes; Nathan R West; Melanie Olson; Jenny E Chu; Peter H Watson
Journal:  Breast Cancer Res       Date:  2008-06-06       Impact factor: 6.466

5.  Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer.

Authors:  Elin Karlsson; Ulla Delle; Anna Danielsson; Björn Olsson; Frida Abel; Per Karlsson; Khalil Helou
Journal:  BMC Cancer       Date:  2008-09-08       Impact factor: 4.430

Review 6.  Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine.

Authors:  Lance D Miller; Edison T Liu
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

7.  Recent translational research: microarray expression profiling of breast cancer--beyond classification and prognostic markers?

Authors:  Cindy A Wilson; Judy Dering
Journal:  Breast Cancer Res       Date:  2004-07-19       Impact factor: 6.466

8.  Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative.

Authors:  L Rydén; N Loman; C Larsson; C Hegardt; J Vallon-Christersson; M Malmberg; H Lindman; A Ehinger; L H Saal; Å Borg
Journal:  Br J Surg       Date:  2018-01       Impact factor: 6.939

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.